View Older Stories View More Recent Stories

Mar 16, 2020 08:00AM Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19
Feb 4, 2020 02:07AM Sanofi investigated over epilepsy drug linked to birth defects
Jan 28, 2020 06:14AM Regeneron (REGN), Sanofi (SNY) Report FDA Accepts Priority Review Dupixent (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
Jan 28, 2020 01:00AM Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
Dec 10, 2019 08:31AM Sanofi (SNY) and Regeneron (REGN) to restructure Antibody collaboration for Kevzara and Praluent
Dec 10, 2019 08:30AM Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
Dec 2, 2019 08:31AM Ligand Pharma (LGND) Enters into Worldwide OmniAb Platform License Agreement with Sanofi (SNY)
Dec 2, 2019 07:31AM Baxter (BAX) to acquire Seprafilm Adhesion Barrier from Sanofi (SNY) for $350 Million
Oct 29, 2019 08:15AM Regeneron (REGN) Announces Dupixent is Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis
Oct 29, 2019 08:15AM Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
Sep 20, 2019 07:01AM Regeneron (REGN), Sanofi (SNY) Report Publication of Results from Two Positive Phase 3 Trials of Dupixent (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps
Sep 20, 2019 06:48AM Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  
Sep 20, 2019 06:44AM Regeneron (REGN) Announces CHMP Recommended Approval of Dupixent for Severe Chronic Rhinosinusitis with Nasal Polyposis
Sep 16, 2019 06:36AM Sanof (SNY), Abbott (ABT) Partner to Integrate Glucose Sensing and Insulin Delivery Technologies
Sep 16, 2019 01:00AM Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
Aug 28, 2019 04:35PM Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
Aug 6, 2019 05:57AM Regeneron (REGN) Reports Dupixent Granted European Commission Approval for Adolescents with Moderate-to-Severe Atopic Sermatitis
Aug 6, 2019 05:48AM Regeneron (REGN) Highlights Positive Topline Results in Phase 3 Trial
Aug 6, 2019 01:05AM Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
Aug 6, 2019 01:00AM Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
Jul 1, 2019 10:02AM Sanofi (SNY) announces Libtayo approved for advanced cutaneous squamous cell carcinoma in European Union
Jul 1, 2019 10:00AM Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
Jun 28, 2019 07:03AM Sanofi (SNY) announces CHMP recommends approval of Dupixent for moderate-to-severe atopic dermatitis in adolescents
Jun 28, 2019 07:00AM Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Jun 28, 2019 06:59AM Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (SNY) Report CHMP Approval of Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
Jun 26, 2019 01:30PM Regeneron (REGN), Sanofi Announce FDA Approval of Dupixent for Chronic Rhinosinusitis with Nasal Polyposis
Jun 26, 2019 01:30PM FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
Jun 26, 2019 01:30PM Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
Jun 21, 2019 05:52AM Regeneron (REGN), Sanofi (SNY) Report Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
Jun 21, 2019 01:00AM Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
Jun 17, 2019 07:33AM Voyager Therapeutics (VYGR) Reports Restructured Gene Therapy Relationship with Sanofi (SNY) Genzyme; Provides Portfolio Update
May 21, 2019 08:00AM Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
May 7, 2019 09:07AM Sanofi (SNY), Regeneron (REGN) Report Dupixent (dupilumab) Approved for Severe Asthma by European Commission
May 7, 2019 09:01AM Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
Apr 26, 2019 07:21PM Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
Apr 26, 2019 11:18AM Regeneron (REGN) Announces CHMP Issues Positive Opinion for Libtayo (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma
Apr 26, 2019 11:17AM CHMP issues positive opinion for Libtayo in advanced cutaneous squamous cell carcinoma (REGN) (SNY)
Apr 26, 2019 11:16AM CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
Apr 8, 2019 06:32AM Alnylam Pharma (ALNY), Sanofi (SNY) Conclude Research and Option Phase of RNAi Therapeutics Collaboration
Mar 15, 2019 07:40PM Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Mar 13, 2019 07:07AM Regeneron (REGN) and Sanofi (SNY) to Present New Praluent Data at ACC
Mar 11, 2019 03:45PM FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Mar 8, 2019 05:56AM Sanofi (SNY), Regeneron (REGN) Report FDA to Undertake Priority Review of Dupixent (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Mar 8, 2019 01:02AM Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
Mar 8, 2019 01:02AM Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
Mar 8, 2019 01:00AM Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
Mar 1, 2019 08:38AM Regeneron (REGN), Sanofi (SNY) Report CHMP Recommends Approval of Dupixent (dupilumab) for Asthma Indication
Mar 1, 2019 08:14AM Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
Feb 25, 2019 04:58PM Amgen (AMGN) Confirms Jury Upholds Its Patents on Repatha
Feb 25, 2019 12:46PM Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
View More Recent Stories View Older Stories